Application
WB analysis of of extracts from HepG2 and HL60 cells untreated or treated with TNF using NFkB p65 (phospho Ser536) antibody.Application
IHC-P analysis of human breast carcinoma using NFκB p65 (phospho Ser536) antibody.Application
IHC-P analysis of human Lung carcinoma using NFκB p65 (phospho Ser536) antibody.Application
ICC/IF analysis of methanol-fixed MEF cells using NFκB p65 (phospho Ser536) antibody.Application
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using NF kappa B-p65 (Phospho-Ser536) Antibody (left) or the same antibody preincubated with blocking peptide (right).Application
Western blot analysis of extracts from HepG2 and HL60 cells untreated or treated with TNF using NF kappa B-p65 (Phospho-Ser536) Antibody .Application
Immunofluorescence staining of methanol-fixed Hela cells using NF kappa B-p65 (Phospho-Ser536) Antibody .| Product Name | NFkB p65 (phospho Ser536) antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Rabbit Polyclonal antibody to NF kappa B-p65 (Phospho Ser536)NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. |
| Immunogen | Peptide sequence around phosphorylation site of serine 536 (F-S-S(p)-I-A) derived from Human NF kappa B-p65. |
| Modification | p-Ser536 |
| Clonality | Polyclonal |
|---|---|
| Host Species | Rabbit |
| Tested Applications | ICC/IFIHC-PWB |
| Suggested starting dilutions are as follows. WB: 1:500~1:1000, IHC-P: 1:50~1:100, ICC/IF: 1:100~1:200. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.: |
|
| Species Reactivity | HumanMouseRat |
| Concentration | 1mg/ml (Please refer to the vial label for the specific concentration) |
| Purification | Affinity purified |
| Gene Synonyms | MGC131774 NFKB3 p65 RELA nuclear factor NF-kappa-B p65 subunit transcription factor p65 NF-kappa-B p65delta3 nuclear factor of kappa light polypeptide gene enhancer in B-cells 3 v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|---|---|
| Target | NF kappa B-p65 (Phospho Ser536) |
| Molecular Weight(MW) | 65 (note) |
Application
WB analysis of of extracts from HepG2 and HL60 cells untreated or treated with TNF using NFkB p65 (phospho Ser536) antibody.
Application
IHC-P analysis of human breast carcinoma using NFκB p65 (phospho Ser536) antibody.
Application
IHC-P analysis of human Lung carcinoma using NFκB p65 (phospho Ser536) antibody.
Application
ICC/IF analysis of methanol-fixed MEF cells using NFκB p65 (phospho Ser536) antibody.
Application
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using NF kappa B-p65 (Phospho-Ser536) Antibody (left) or the same antibody preincubated with blocking peptide (right).
Application
Western blot analysis of extracts from HepG2 and HL60 cells untreated or treated with TNF using NF kappa B-p65 (Phospho-Ser536) Antibody .
Application
Immunofluorescence staining of methanol-fixed Hela cells using NF kappa B-p65 (Phospho-Ser536) Antibody .| Application Notes | Suggested starting dilutions are as follows. WB: 1:500~1:1000, IHC-P: 1:50~1:100, ICC/IF: 1:100~1:200. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.: |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Keep as concentrated solution. Aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
